

# ceftAROLine

BRAND NAME ZINFORO

DRUG CLASS Cephalosporin antibiotic

AVAILABILITY Vial contains 600 mg of ceftaroline fosamil. Also contains L-arginine.<sup>1</sup>

## WARNINGS

Contraindicated in patients with severe immediate (IgE mediated) or severe delayed (T-cell mediated) hypersensitivity to penicillins. Seek specialist advice for patients with non-severe immediate hypersensitivity to penicillins.

pH 5–7 when diluted<sup>1</sup>

## PREPARATION

Reconstitute the vial with 20 mL of water for injections to make an approximate concentration of 30 mg/mL. Shake well. The solution is pale yellow.<sup>1</sup>

Further dilute the reconstituted solution immediately.<sup>1</sup>

If a part-dose is required, reconstitute the vial with 19.3 mL of water for injections to make a concentration of 30 mg/mL.<sup>2</sup> Powder volume – 0.7 mL<sup>2</sup>

## STABILITY

Vial: store below 25 °C. Protect from light.<sup>1</sup>

Reconstituted solution: dilute immediately.<sup>1</sup>

Infusion solution: stable for 6 hours at room temperature or 24 hours at 2 to 8 °C.<sup>1</sup>

For CoPAT use: solutions of 6 mg/mL in sodium chloride 0.9% are stable for 24 hours at 25 °C or 12 hours at 30 °C or 35 °C. Stability in glucose is reduced at higher temperatures.

Solutions prepared in a sterile production unit are stable for 6 days at 4 °C.<sup>3</sup>

## ADMINISTRATION

**IM injection** Not recommended

**SUBCUT injection** Not recommended

**IV injection** Not recommended

**IV infusion** Dilute the dose in 50–250 mL of compatible fluid. The maximum concentration is 12 mg/mL. Infuse over 5 to 60 minutes.<sup>1</sup>

High doses may be given as an extended infusion in critically-ill patients.<sup>1</sup> Check your local guidelines.

## IV use for infants and children

Dilute the dose to 12 mg/mL or less and infuse over 5 to 60 minutes. For children less than 2 months old, infuse over 30 to 60 minutes.<sup>1,4</sup>

## COMPATIBILITY

**Fluids** Glucose 5%<sup>1</sup>, glucose 2.5% and sodium chloride 0.45%<sup>1</sup>, Hartmann's<sup>1</sup>, sodium chloride 0.9%<sup>1</sup>

**Y-site** Aciclovir<sup>5</sup>, aminophylline<sup>5</sup>, amiodarone<sup>5</sup>, azithromycin<sup>5</sup>, calcium chloride<sup>5</sup>, calcium gluconate<sup>5</sup>, ciclosporin<sup>5</sup>, ciprofloxacin<sup>5</sup>, cisatracurium<sup>5</sup>, clindamycin<sup>5</sup>, dexamethasone<sup>5</sup>, digoxin<sup>5</sup>, esomeprazole<sup>5</sup>, fentanyl<sup>5</sup>, fluconazole<sup>5</sup>, furosemide<sup>5</sup>, granisetron<sup>5</sup>, heparin sodium<sup>5</sup>, hydrocortisone sodium succinate<sup>5</sup>, hydromorphone<sup>5</sup>, insulin (Actrapid)<sup>5</sup>, lidocaine<sup>5</sup>, mannitol<sup>5</sup>, methylprednisolone sodium succinate<sup>5</sup>, metoclopramide<sup>5</sup>, metoprolol<sup>5</sup>, metronidazole<sup>5</sup>, midazolam<sup>5</sup>, milrinone<sup>5</sup>, morphine sulfate<sup>5</sup>, moxifloxacin<sup>5</sup>, noradrenaline (norepinephrine)<sup>5</sup>, pethidine<sup>5</sup>, potassium chloride<sup>5</sup>, promethazine<sup>5</sup>, ranitidine<sup>5</sup>, remifentanyl<sup>5</sup>, sodium bicarbonate<sup>5</sup>, trimethoprim-sulfamethoxazole<sup>5</sup>, voriconazole<sup>5</sup>

## INCOMPATIBILITY

**Fluids** No information

**Drugs** Aminoglycosides: amikacin, gentamicin, tobramycin<sup>1</sup>, caspofungin<sup>6</sup>, filgrastim<sup>6</sup>, fosfomycin<sup>6</sup>, isavuconazole<sup>6</sup>, labetalol<sup>6</sup>, potassium phosphates<sup>6</sup>, sodium phosphates<sup>6</sup>

## SPECIAL NOTES

Monitor the infusion site closely as infusion-site reactions are common and include erythema, phlebitis and pain.<sup>1</sup>

## REFERENCES

1. Product information. Available from [www.tga.gov.au](http://www.tga.gov.au). Accessed 28/04/2021.
2. Pfizer medical information. Pfizer enquiry INT-102254 [email]. Sydney: Pfizer; 03/03/2021.
3. Al Madfai F, Zaidi STR, Ming LC, Wanady T, Patel RP. Physical and chemical stability of ceftaroline in an elastomeric infusion device. *Eur J Hosp Pharm Sci Pract*. 2018; 25e: 115-9.
4. Taketomo C, Hodding J, Kraus D. Pediatric and neonatal dosage handbook. 27th ed. Hudson, Ohio: American Pharmacists Association. Lexicomp; 2020-2021.
5. McEvoy GK editor. Handbook on injectable drugs. 20th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2018.
6. Ceftaroline fosamil. In: IV index [internet]. Trissel's 2 clinical pharmaceuticals database (parenteral compatibility). Greenwood Village, CO: Truven Health Analytics. Accessed 28/04/2021.